By Application
Hot products 
-
Mouse Anti-CD24 Recombinant Antibody (2Q1282) (CBMAB-C1624-CN)
-
Mouse Anti-AQP2 Recombinant Antibody (G-3) (CBMAB-A3359-YC)
-
Rabbit Anti-ADRA1A Recombinant Antibody (V2-12532) (CBMAB-1022-CN)
-
Mouse Anti-AKR1C3 Recombinant Antibody (V2-12560) (CBMAB-1050-CN)
-
Mouse Anti-GDF5 Recombinant Antibody (1F4) (CBMAB-G2740-LY)
-
Rabbit Anti-BAD (Phospho-Ser136) Recombinant Antibody (CAP219) (CBMAB-AP536LY)
-
Mouse Anti-FOXA3 Recombinant Antibody (2A9) (CBMAB-0377-YC)
-
Mouse Anti-AKR1B1 Antibody (V2-2449) (CBMAB-1001CQ)
-
Mouse Anti-AQP2 Recombinant Antibody (E-2) (CBMAB-A3358-YC)
-
Armenian hamster Anti-CD40 Recombinant Antibody (HM40-3) (CBMAB-C10365-LY)
-
Mouse Anti-DLC1 Recombinant Antibody (D1009) (CBMAB-D1009-YC)
-
Mouse Anti-ESR1 Recombinant Antibody (Y31) (CBMAB-1208-YC)
-
Mouse Anti-ACO2 Recombinant Antibody (V2-179329) (CBMAB-A0627-YC)
-
Mouse Anti-BIRC3 Recombinant Antibody (16E63) (CBMAB-C3367-LY)
-
Mouse Anti-BAD (Phospho-Ser136) Recombinant Antibody (CBYY-0138) (CBMAB-0139-YY)
-
Mouse Anti-ADGRE2 Recombinant Antibody (V2-261270) (CBMAB-C0813-LY)
-
Mouse Anti-Acetyl-α-Tubulin (Lys40) Recombinant Antibody (V2-623485) (CBMAB-CP2897-LY)
-
Mouse Anti-CECR2 Recombinant Antibody (CBWJC-2465) (CBMAB-C3533WJ)
-
Mouse Anti-GluRIIA Monoclonal Antibody (8B4D2) (CBMAB-0305-CN)
-
Mouse Anti-CEMIP Recombinant Antibody (3C12) (CBMAB-K0296-LY)
Skin Cancer (SCC)
Fig.1 Squamous cell skin cancer
Squamous-cell skin cancer, also named as cutaneous squamous-cell carcinoma (cSCC), is one of the typical types of skin cancer along with melanoma and basal cell cancer. Normally, it presents as a hard lump with a scaly top but can also deteriorate into an ulcer. Onset is often several months. Squamous-cell skin cancer is more likely to spread to distant areas comparing with basal cell cancer. The greatest risk factor is the high total exposure to ultraviolet radiation from the sun. Squamous cell cancers happening in the ears and lip have high possibilities of local recurrence and distant metastasis (about 20–50%). SCCs represent around 20% of the non-melanoma skin cancers, but on account of their more obvious nature and growth rates, they stands for 90% of all head and neck cancers that are primarily presented. CD10, as a novel marker of therapeutic resistance and cancer stem cells in head and neck squamous cell carcinoma, has been studied.
